387 related articles for article (PubMed ID: 12208877)
1. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
[TBL] [Abstract][Full Text] [Related]
2. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Brusic V; Sidney J; Sette A; Logan TF; Kasamon YL; Slingluff CL; Kirkwood JM; Storkus WJ
Clin Cancer Res; 2003 Mar; 9(3):947-54. PubMed ID: 12631591
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
4. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
[TBL] [Abstract][Full Text] [Related]
5. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
[TBL] [Abstract][Full Text] [Related]
6. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
8. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ
Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683
[TBL] [Abstract][Full Text] [Related]
9. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.
Ohkuri T; Wakita D; Chamoto K; Togashi Y; Kitamura H; Nishimura T
Br J Cancer; 2009 Apr; 100(7):1135-43. PubMed ID: 19277034
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
12. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame.
Slager EH; Borghi M; van der Minne CE; Aarnoudse CA; Havenga MJ; Schrier PI; Osanto S; Griffioen M
J Immunol; 2003 Feb; 170(3):1490-7. PubMed ID: 12538712
[TBL] [Abstract][Full Text] [Related]
13. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
[TBL] [Abstract][Full Text] [Related]
14. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.
Kierstead LS; Ranieri E; Olson W; Brusic V; Sidney J; Sette A; Kasamon YL; Slingluff CL; Kirkwood JM; Storkus WJ
Br J Cancer; 2001 Nov; 85(11):1738-45. PubMed ID: 11742496
[TBL] [Abstract][Full Text] [Related]
15. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.
Schuler-Thurner B; Schultz ES; Berger TG; Weinlich G; Ebner S; Woerl P; Bender A; Feuerstein B; Fritsch PO; Romani N; Schuler G
J Exp Med; 2002 May; 195(10):1279-88. PubMed ID: 12021308
[TBL] [Abstract][Full Text] [Related]
16. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.
Chikamatsu K; Sakakura K; Takahashi G; Okamoto A; Furuya N; Whiteside TL; DeLeo AB; Masuyama K
Cancer Immunol Immunother; 2009 Sep; 58(9):1441-8. PubMed ID: 19184003
[TBL] [Abstract][Full Text] [Related]
18. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
Damico FM; Cunha-Neto E; Goldberg AC; Iwai LK; Marin ML; Hammer J; Kalil J; Yamamoto JH
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2465-71. PubMed ID: 15980237
[TBL] [Abstract][Full Text] [Related]
19. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
Parkhurst MR; Riley JP; Robbins PF; Rosenberg SA
J Immunother; 2004; 27(2):79-91. PubMed ID: 14770079
[TBL] [Abstract][Full Text] [Related]
20. Effect of renal cell carcinomas on the development of type 1 T-cell responses.
Rayman P; Wesa AK; Richmond AL; Das T; Biswas K; Raval G; Storkus WJ; Tannenbaum C; Novick A; Bukowski R; Finke J
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6360S-6S. PubMed ID: 15448031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
